

Table S1. Oligonucleotide primers used in this study.

Primer	Nucleotide Sequence
SpuAF	5'-CACCCATATGGCTAGCGATAACTACTTCCGTATC-3'
SpuAR	5'-GGATCCCTCGAGTTATTACAGCTTGTTTATCTGGGGTTGC-3'
MALXF	5'-TATATAGCTAGCGATAAGCCTGCTGATTCTGGTTCATCTGAATCAC-3'
MALXR	5'-GCGCGCCTCGAGTTATTATTACCAAATTTTGTGTTGATTGTTTCTT-3'
CAM-F	5'-TTTGGAGCTAGCGATGAAAATTTGTTTGAT- 3'
CAM-R	5'-CTTTGTCTCGAGGTACAGTCCGGCATTATC- 3'
SpuA-1F	5'-AACGTACCCCTGGAAGGTCT-3'
SpuA -1R*	5'-CATATGGCTAGCGAGGGAACGGATGCTGTAGA-3'
SpuA -2F	5'-GTGGTGCTCGAGCAGGAATCAGCCTCCTTGC-3'
SpuA -2R	5'-TGACTCAAACGATTGCTGGT-3'
MalX-1F	5'-GGAAGGATTTGCCAGTAACG- 3'
MalX-1R*	5'-GCAAGCTACCAAAAGCAAGC- 3'
MalX-2F	5'-GTGGTGCTCGAGCAGCTGCTAACGATGCTGTAA- 3'
MalX-2R	5'-GCCAAAGCCCAAATGATAGT- 3'

*an *NheI* restriction site was located just upstream of the primer site

Engineered restriction sites are underlined; *NheI* is GCTAGC and *XhoI* is CTCGAG.